SGLT-2 inhibitor use vs DPP-4 inhibitor use was associated with a lower risk for incidental Parkinson disease among older adults with type 2 diabetes.

For patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is associated with reduced risks for incident dementia and Parkinson disease (PD).

Those who receive the COVID-19 vaccine during pregnancy are less likely to be hospitalized for COVID-19; however, vaccine uptake in this population is suboptimal.

Long COVID is common among veterans in the Airborne Hazards and Open Burn Pit Registry; however, the risk is not augmented by deployment exposures.

Greater Mediterranean-Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) diet adherence is associated with a reduced risk for cognitive impairment.

FDA alerts in gastroenterology over the summer included an approval for a biosimilar for IBD & new indications for nonerosive ...

Opioid use is more prevalent among individuals with vs without IBD, although not related to a psychiatric comorbidity.

The acetaminophen cysteine adduct assay slightly improves the accuracy in diagnosing between acetaminophen hepatoxicity and ischemic hepatic injury.

The FDA has granted Breakthrough Therapy to plozasiran for use to reduce triglycerides in familial chylomicronemia syndrome.

A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with chronic hepatitis B (CHB).

Sepsis mortality, including a 28-day mortality, is associated with a genetic predisposition to gastroesophageal reflux disease.

SGLT-2 inhibitors were associated with the lowest risk for incidental dementia relative to DPP-4 inhibitors and GLP-1RAs in type 2 diabetes.